Highlights AEON Biopharma, Inc.

Equities

AEON

US00791X1000

Market Closed - Nyse Other stock markets 04:00:00 2024-06-10 pm EDT			5-day change	1st Jan Change
1.5 ^USD	-10.71%		-8.54%	-79.17%

May. 16	AEON Biopharma, Inc. Announces Termination of Peter Reynolds as Chief Financial Officer, Effective May 17, 2024	CI
May. 16	AEON Biopharma, Inc. Announces Executive Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AEON Biopharma, Inc. Deloitte, Inc. Announces Update of Phase 2 Double Blind Study of ABP-450 in the Treatment of Migraine	May. 16	CI
AEON Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
AEON Biopharma, Inc. Provides Update on Development Pipeline	May. 09	CI
US Equity Markets Close Higher Friday Following Weak Jobs Report	May. 03	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	May. 03	MT
Sector Update: Health Care	May. 03	MT
Top Midday Decliners	May. 03	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	May. 03	MT
AEON Biopharma Shares Slump Pre-Bell After Failed Chronic Migraine Phase 2 Trial	May. 03	MT
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine	May. 03	CI
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 01	MT
Sector Update: Health Care	Apr. 01	MT
AEON Biopharma Shares Tumble on Wider Q4 Loss	Apr. 01	MT
AEON Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
AEON Biopharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 29	CI
AEON Biopharma, Inc. Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine	Mar. 19	CI
AEON Biopharma, Inc. Presents Positive Clinical and Pre-Clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, At TOXINS 2024	Jan. 18	CI
AEON Biopharma, Inc. Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine	Dec. 12	CI
AEON Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
AEON Biopharma, Inc. Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine	23-10-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AEON Biopharma, Inc.

Equities

AEON

US00791X1000

Highlights

Filters